#42 PACAP and the future of migraine treatment – with Haidar Al-Khazali, MD, PhD

In episode 42 of Migränpodden, our first in English, we speak with Haidar Al-Khazali, a researcher at the Danish Headache Center. Haidar explains how research on the protein PACAP could hopefully lead to new migraine medications in the near future.

Music: Sharing Silence by KORALL. From the album Psychedelic Sunblock.

Haidar Al-Khazali: And this is basically to say that we have not solved the migraine puzzle so far. We need to understand more and more why we have migraine, and then we need to come with more than one drug because, we need to think about maybe for one person, the, the thing that drives their headache, their migraine could, for example, be PACAP. For another person it could be CGRP. For a third person it could be both of them.

Leonora: Hello and a warm welcome to Migränpodden, a Swedish podcast about migraine. After 41 episodes in Swedish, we’re doing an episode in English for the very first time. We’re Leonora Mujkic and Malin Östblom. We both live with migraine ourselves, and we make this podcast because we’re passionate about spreading knowledge about migraine.

Malin: I’m Malin, and as always, a quick reminder: on this podcast we talk about migraine as a disease and everything that comes with it, but we don’t give any medical advice or recommendations. That’s the job of healthcare professionals. What we hope is that our conversations can spark thoughts and ideas that you can take further in your own way.

Leonora: That’s right. And I’m Leonora. As we said, Malin and I usually make this podcast in Swedish, but in this episode we’re interviewing a Danish researcher in English. We think this is research that a lot of people living with migraine will find interesting. Maybe it can even give some hope for a future with fewer attacks and a better quality of life. Today we’re talking to Haidar Al Khazali, who works at the Danish Headache Center and is part of Professor Messoud Ashina’s research group. This conversation is all about their research on a new substance called PACAP. It’s research that will hopefully lead to new migraine drugs in the not-too-distant future.

Malin: Exactly. Over the past few years, many of us have learned quite a bit about the abbreviation CGRP. Today we’re going to learn a different one: PACAP. Before the interview, we thought there would be lots of terms we would need to explain in the introduction. But that didn’t really happen, because Haidar was so keen to talk about the research on PACAP in a way that makes sense even to those of us who aren’t familiar with this topic.

Leonora: True. Still, it’s a lot of very exciting information to digest, so we’ve decided to split the interview into two episodes. Let’s listen to the first part of our interview with Haidar Al-Khazali.

Start of interview with Haidar Al-Khazali

[00:04:33] Malin Östblom: Welcome to Migränpodden, Haidar Al-Khazali. You are a neuroscientist and currently a post-doctoral research fellow at the Danish Headache Center, one of the leading research environments in migraine and other headache disorders. The focus of your research is migraine, post-traumatic headache and cluster headache. The topic of our conversation today will mostly be your research on PACAP, which seems to be a promising new target in migraine treatment. And so exciting. again, welcome to Migränpodden. We are so very happy, almost ecstatic about having you here. So welcome. 

[00:05:16] Haidar Al-Khazali: Thank you very much, Malin, and also, Leonora, for inviting me to have this very interesting topic about PACAP and the pathophysiology of headache, not only migraine, right?

[00:05:26] Malin Östblom: Right. 

[00:05:26] Haidar Al-Khazali: So thank you for inviting me. 

[00:05:28] Malin Östblom: Would you start, by telling us a bit about yourself, maybe about your background, education, and, maybe a little bit about your areas when it comes to research, and currently what you are focusing in on right now? 

[00:05:40] Haidar Al-Khazali: Well, I have a background in medicine, so I’m a medical doctor, and I have made a PhD also at the Danish Headache Center, focusing on migraine and especially CGRP, another molecule we will talk about later, and the new treatments, and to see whether we can predict who is a good responder and who’s a bad responder to these treatments. So that has been my focus and my PhD. But along this journey, I have also focused on my work on, post-traumatic headache, so headache after a concussion, as well as cluster headache. And in general, across these three different headache disorders, my focus is about understanding what triggers or starts the headache.

Because this is a very good question. And if we as doctors, as physicians and also patient understand what starts the headache, maybe we can also help with the treatments against the headache and try to prevent it in one way or another. So this is in very short words what I’m doing. Tryin to understand the basic mechanisms behind the headache and maybe by this approach try to prevent it or treat it with newer drugs.

[00:06:48] Malin Östblom: So exciting! And PACAP seems to be a promising new treatment and that this might be a treatment or a target for migraine. And we’ll, we’ll start with the basic. What does the abbreviation PACAP actually stand for and what is it? 

[00:07:05] Haidar Al-Khazali: PACAP is basically standing for pituitary adenylate cyclase activating polypeptide. So it’s very, very long, very, very heavy. Just remember PACAP. Five letters. It’s much easier to remember. And this is basically a protein. We can also call it a neuropeptide, but it is basically a protein that is in every human being. So not only people with migraine, it is in everyone. And we also see this protein in animals as well. And by the research, we have discovered that this is a very important molecule, a very important protein that has many, many different functions. It’s known for its effect in the context of vasodilation. It means that it dilates, it make the vessels within the body larger, so it increases the diameter of the vessels.

Okay? So this is what we call vasodilation. It can regulate the vessel diameter. It also has a role in inflammation and also has a role in how the cells within the brain can communicate with each other. But today’s topic will only focus on its effect in migraine. And in migraine, it has been shown that this protein has a key role in the starting, in the genesis of the migraine headache.

So if I just go back and explain what is migraine, because this is also very fascinating. I know that the listeners and you live with this disease, but, it’s very important to say that migraine is a headache, and it’s more than just a headache. And why do we have this problem? We have this because we have a problem with the system we call the trigeminovascular system. It’s a system in the brain where there is a problem with the nerve number five. We call this fifth nerve the trigeminal nerve. It’s basically the nerve that, has something with the sensation in the face. So when you touch yourself, either smoothly or aggressively, will register a kind of a touch or sensation. This is because of this nerve, the fifth nerve. We call this the trigeminal nerve. It has been shown with animal studies that activation of this system, the trigeminovascular system, activation of this system releases different proteins, and one of these is also PACAP. 

[00:09:32] Haidar Al-Khazali: So by this, we and other, researchers has then, raised the question, since we can see that this, protein is released when the system is activated, what will happen if we give a patient, either a healthy participant, a healthy person who’s not suffering from any headache, PACAP infusion.

PACAP, we can give it in many ways, but one way is to do it in, in the veins. So we can give it to a person who’s not suffering from headache. We can also give the same PACAP to a person with just few days of headache. We can call this person with episodic migraine, for example. And by this line of evidence, it has been shown that when you give or introduce PACAP to a person not suffering from migraine, this patient will, or this participant will develop nothing or a mild headache.

[00:10:19] Leonora Mujkic: We’re talking here about people who have no history of migraine or don’t have any relatives who have migraine. So they, they’ve never had migraine before. Yeah? 

[00:10:28] Haidar Al-Khazali: Exactly. So this is the control group. Okay. So when you give it to a participant who’s the control group, they will develop nothing or just a mild headache, and this headache will disappear by itself within few hours, for example. If you give the same dosage of PACAP in the veins to a person with just few days of migraine, so a person with the diagnosis of migraine, this patient will, in up to sixty percent of cases, develop a migraine attack.

So this indicates that we have a different threshold for this protein we have in our body. If you are a person not suffering from headache, the control, or if you are a person with just few days of headache, for example, in this context. And that was a study that was conducted in 2009. 

[00:11:12] Leonora Mujkic: So that’s long ago.

[00:11:14] Haidar Al-Khazali: Yeah. So in 2009, that was the first approval that PACAP has a role in the genesis of migraine Before that time it has only been suggested, and investigated, let’s say with maybe blood samples and also animal studies. But in humans, that was the first piece of evidence that PACAP has a role in humans with migraine.

[00:11:34] Leonora Mujkic: And when you say threshold, did you mean that, the threshold for how much PACAP a person with migraine can tolerate is lower, and that’s why the problem is that when you give an infusion of this peptide? Or do you mean that, how much PACAP the person already has is higher? What’s the threshold about? 

[00:11:54] Haidar Al-Khazali: It’s a very, very good question. If I give you, let’s say an X amount of PACAP. For you, let’s say, just an example, five, and for you five of PACAP will induce migraine to you. 

[00:12:10] Leonora Mujkic: Yeah. 

[00:12:10] Haidar Al-Khazali: For me, maybe I’m not a person with migraine, and I don’t suffer from migraine. Maybe for me to get a migraine attack, I need maybe 20, for example. So the threshold between you and me is different. 

[00:12:22] Leonora Mujkic: Ah, that’s interesting. 

[00:12:23] Haidar Al-Khazali: So, basically by this study, published in 2009, it was shown that PACAP infusion can lead to migraine attack in people with migraine, but in the comparison group, the control group, it did not. It only induced, or triggered a mild headache. 

[00:12:38] Leonora Mujkic: Okay. 

[00:12:38] Haidar Al-Khazali: And this line of evidence was the first piece that indicated that PACAP has a role in migraine. Now, we need to think about that PACAP is basically, in two variants, two forms in the body. 

[00:12:51] Leonora Mujkic: Okay. 

[00:12:52] Haidar Al-Khazali: The most important part, not important, but the most frequent part is the one called PACAP-38. As I mentioned, PACAP is a protein, so it’s composed of a molecule with 38 amino acids. And then there is the less frequent part, which is PACAP-27. So it’s basically a shorter one. 

[00:13:14] Leonora Mujkic: Okay. 

[00:13:14] Haidar Al-Khazali: So we have two isoforms, two variants of PACAP in our body. 90% of the PACAP in the body is PACAP-38. The less frequent one is PACAP-27. Ten years later, so in 2019, that was tested. PACAP-27, is this also something that can trigger a migraine attack? And it also showed the same thing, that when you give PACAP-27 to people with migraine compared with placebo, it also induced migraine attacks in more than sixty percent of cases.

[00:13:46] Malin Östblom: So they could prove that both of these types of the amino acids actually triggered …

[00:13:55] Haidar Al-Khazali: Exactly. And more than fifty percent of cases in both these studies. So these two studies indicate that PACAP has a key role in the genesis of migraine in humans, right?

[00:14:06] Leonora Mujkic: Yes. 

[00:14:06] Haidar Al-Khazali: And that afterwards led the researchers to come with drugs against this pathway.

[00:14:13] Leonora Mujkic: Okay. And these are drug candidates to be researched on for a probably long time before we can see that this actually works and is safe? And are there drug candidates using both PACAP-38 and PACAP-27?

[00:14:30] Haidar Al-Khazali: Well, that’s a good question because the one we have now, the one we have now refers to that we have multiple studies, if we go back in time, that has tried to block the PACAP pathway. Okay? And some of them has failed. We will come to this later. But the one who has been shown to have some positive results is an antibody, so a big molecule that blocks the PACAP molecule itself.

[00:14:56] Leonora Mujkic: Okay. So not the receptor, but the molecule itself. 

[00:14:59] Haidar Al-Khazali: Exactly. And the molecule means both molecules, both PACAP-27 and 38. So this is very important to remember, okay? Not the receptors, the molecule PACAP itself. 

[00:15:10] Leonora Mujkic: And could you explain what those two mean, in a way that normal people can understand: blocking the molecule, versus, blocking the receptor?

[00:15:17] Haidar Al-Khazali: Yeah. So now we know, we have shown, or this has been shown, that PACAP has a role in the migraine development. And so for you to come with a treatment, you either need to block the protein itself or the receptor. So just imagine if we have, for example, a room with door, with one door, and, you, you have PACAP could be, for example, the key to this door. Okay, so if you don’t want this door to be opened, you can either block the key and don’t have the key going into the lock and open the door. Or you can just block the door itself. 

[00:15:56] Haidar Al-Khazali: So remember or just imagine that the key here is PACAP. You can either block this part or, or the receptor could be the door, so you block the door. So these are basically the two approaches you need to think about when you talk about treatments development. So either you block the molecule or the receptor, the key or the door. 

[00:16:15] Malin Östblom: And with the CGRP drugs, they work in different way because they are like antibodies, right? For the CGRP molecule. 

[00:16:25] Haidar Al-Khazali: For the CGRP, it is the same. So we have both antibodies blockers that block the door or block the molecule, the key, for example, the CGRP key.

[00:16:35] Malin Östblom: Right. 

[00:16:35] Haidar Al-Khazali: But, for PACAP, for now we only have for blocking the ligand, or the molecule itself. 

[00:16:46] Malin Östblom: Okay. But they are both vasodilators. Is that correct? 

[00:16:50] Haidar Al-Khazali: Yeah. 

[00:16:50] Malin Östblom: And what is the difference? 

[00:16:52] Haidar Al-Khazali: With both you refer to CGRP, just for the listener.

[00:16:57] Malin Östblom: Mm. 

[00:16:57] Haidar Al-Khazali: CGRP stands for calcitonin gene-related peptide. It’s also a protein like PACAP, and it has also the same abilities, so it increases the diameter of the vessels. And that was shown in 2002, that when you give CGRP to people with migraine, they will develop a migraine attack.

And then, in 2018, first there, so we have 16 years where to basically to come with these new drugs. And now we have drugs against the CGRP pathway. And as you mentioned, we have both antibodies which are big molecules. And these big molecules can block the CGRP molecule or the CGRP receptor, the door. These are antibodies, but we also have another class of drugs, which are those we call gepants. These are small molecules, and these are only blocking the CGRP receptor. 

[00:17:52] Leonora Mujkic: So that’s the difference between the antibodies and the gepants. Okay. 

[00:17:56] Haidar Al-Khazali: Exactly. And another thing is also that these drugs have made life so much better for so many people with migraine, these new anti CGRP treatments.

And if you look across the different data, it’s about fifty percent of people with migraine who are responders. But on the other side, we still have about fifty percent or maybe more who do not respond or who are partial responders to these treatments. And this is basically to say that we have not solved the migraine puzzle so far.

We need to understand more and more why we have migraine. And then we need to come with more than one drug because, we need to think about maybe for one person, the thing that drives their migraine could, for example, be PACAP. For another person, it could be CGRP. For a third person, it could be both of them.

And this is something we need to think about when we talk about treatment. And there’s also another important thing I would like to mention. That we have some overlaps with CGRP and PACAP. As you mentioned, we have this in increase of the diameter of the vessels. Both we see this, as an event after PACAP and also after, CGRP. But there are also some differences. One of these differences is that, as I mentioned, the trigeminovascular system, once this system is activated, it will lead to release of different proteins. One is CGRP, another one is PACAP, right? And this is from this fifth nerve, the trigeminal nerve.

[00:19:32] Malin Östblom: As you said, a lot of people have been helped from CGRP, but also a lot of people, as you say, aren’t helped or helped a bit. I went from 25 migraine days a month to maybe 10 migraine days a month. And that’s it seems, for us in the migraine business, that’s amazing. But still it’s like a third of a month with …

[00:20:01] Haidar Al-Khazali: Yeah, yeah. And also a third of a year, right?

[00:20:10] Malin Östblom: So we are so happy that you’re still looking because maybe also it was hard. I don’t know. This is like a question, a long, very long question. Was it hard to keep doing research when this CGRP came? I think that maybe people said, ”Oh, they’ve solved it. This was the holy grail.” 

[00:20:31] Haidar Al-Khazali: But that’s every time. Every time. They said the same also when the introduction of triptans came to the market.

[00:20:37] Malin Östblom: Oh, yes. 

[00:20:38] Haidar Al-Khazali: And that’s many years ago. And, and you still, make research and try to understand, both headache and also migraine. 

[00:20:45] Malin Östblom: So, a salute to you and your group that you keep on, because I think we are a lot of people that say, ”Sorry, but, my life isn’t solved yet.”

[00:20:58] Leonora Mujkic: And it’s also very interesting, because, we, our listeners often contact us. We don’t give any medical advice, of course, because we’re not physicians. We try to refer them to sources that we find reliable and, and perhaps, help them with, ”Okay, but when you go to your doctor, you could bring this or this information.” But, what we find with the new drugs we have, the CGRP antibodies and the gepants, is that many people, including ourselves, Malin and I, also have a different kind of migraine. Not only that the days are perhaps fewer, but also that the attacks are very different.

For example, perhaps for someone, the pain isn’t as severe. For someone else, it’s that they don’t throw up anymore. For someone else, it’s that the light or sound sensitivity isn’t as intense as it used to be. So it’s also not, it’s not an on off switch even for those who are responders. That’s very interesting we think. And, I don’t know if there’s any research done on that, how do these different symptoms change and why? 

[00:22:12] Haidar Al-Khazali: It’s a very important question, but we are not there yet. No. We, we cannot… If you just, ask 100 different people with migraine what triggers, for example, their migraine, right? For some, they will, for example, say, strawberry or dark chocolate. You also hear people say, ”Okay, I think I have migraine because, for example, I live in Sweden or Denmark. The weather here is always gray. It is always raining. When I travel, for example, to Spain or Italy, my headache becomes so much better. Maybe I have this headache or migraine because I live in these countries.” 

[00:22:46] Haidar Al-Khazali: Yeah. But then, we as physicians can say, ”Well, maybe for you it’s right. That this is very true that for your headache, the heat is better.” But we also see that if we look at the prevalence, the number of people with migraine. In Denmark, it’s about ten to fifteen percent. The same number is also in Sweden. Yeah. But the same number is also in Spain. 

[00:23:06] Leonora Mujkic: Yeah. Yeah. 

[00:23:07] Haidar Al-Khazali: So, there are different factors that might improve or, the other way, induce or trigger the migraine. Yeah. And the same is also for when you give them the treatment.

For some people, it will be that now they are not throwing up anymore. For others, it’s that they have maybe these migraine symptoms partial. For example, they have the headache but no more light sensitivity, sound sensitivity. They can maybe still, even though they have the headache, they can be, be physically active, for example.

So, it differs from person to person. And we need to see where is the changes because right now we only evaluate one thing. Yeah. And that is the reduction in migraine days or headache days of moderate to severe intensity. It’s both good and bad because it’s an easy way to evaluate if this treatment works. But the opposite can also be, that if you, for example, evaluate by other things. For example, there is a, a score called the MIDAS score. Where you look at the migraine disability. And that was basically something that was not really good, when you look at, in Italy because now they are not only need … The patients not only need to prove that they have reduction in the headache days. They also need to prove they have a reduction in the migraine days.

So, this is an additional thing before they can get the drug reimbursement. So, both physicians and also patients need to, need to talk together and see where is the outcome we should have as the first outcome. Is it the headache days? Is it the migraine days? Is it both of them? 

[00:24:45] Leonora Mujkic: Is it quality of life?

[00:24:46] Haidar Al-Khazali: Is it quality of life or is it, for example, sleep problems? So these things, is something we need to be aligned of. Yeah. But we also need to think about, okay, will this maybe make the thing for us, for example, in the context of reimbursement, easier or more difficult?

[00:25:02] Leonora Mujkic: Yeah. 

[00:25:02]Haidar Al-Khazali: So this is also something we need to keep in mind. 

[00:25:05] Leonora Mujkic: Could the, well, not maybe solution, but could a benefit be to include patients early on in the research so that we as patients could tell you who are going to do the research what is important to us? One of those standard things is that your most bothersome symptom is reduced after three hours, let’s say. So perhaps for some of us it doesn’t matter if it’s three or five hours, even if it hurts very much or even if you’re throwing up, because the most important thing is perhaps that it doesn’t come back, the attack. 

[00:25:37] Haidar Al-Khazali: Exactly. And this is actually the movement there is now, not only in the headache field, but basically in all the diseases.

So for example, when you need to design a, a trial, a protocol, there is basically a something new, which is you need to include patients. To be part either of the study design or the study analysis or … So, so this is something that will be bigger and bigger within the coming years. 

[00:26:04] Leonora Mujkic: What are your thoughts about that, your and your colleagues? Is that, is that positive or does it interfere with what you guys want to do?

[00:26:11] Haidar Al-Khazali: No, I think it’s a very positive and very good thing because we think maybe by one box. Yeah. And the patient has another box. And then if we brainstorm with each other, we can figure out, okay, maybe this is a very good idea from both sides. So we can basically learn from each other. And by this way, it will maybe also be easier for both parts to communicate. That’s very, very important.

[00:26:49] Leonora Mujkic: We often talk about, Malin and I and also with researchers we’ve interviewed, that people can report what they think is a trigger, but that doesn’t mean it actually is a trigger for a migraine attack. People say chocolate, but it can just as well be that you have the craving to eat something sweet because the migraine attack perhaps started yesterday. Or neck pain being a symptom rather than a trigger, for example. 

[00:27:12] Leonora Mujkic: So is this – what you’re doing, trying to see what actually starts a migraine attack … Do you think could we get better at saying what actually triggers a migraine attack for different people, so people don’t have to be afraid?

Because many of our listeners, and we’ve been there ourselves, we’re so afraid of everything. Someone says, don’t eat, I don’t know, strawberry. ”Don’t drink this, don’t eat cheese. Don’t do this or that.” And then you already have a neurological disease, and you are now living in a box that is just smaller and smaller and smaller because you can’t eat this, you can’t drink that, you can’t be outside when it’s, I don’t know, humid or whatever. 

[00:27:49] Haidar Al-Khazali: Yes. 

[00:27:50] Leonora Mujkic: And then you just have, the quality of life gets worse and worse as the disease gets worse and worse, or the other way around. Who knows what’s what? 

[00:27:58] Haidar Al-Khazali: That’s basically what I’m doing, because, as I mentioned, if you ask a hundred different people what triggers a migraine, we’ll get a hundred different answers. 

[00:28:06] Haidar Al-Khazali: And basically by this, what you’re saying, that’s basically what we as researchers have thought about. Okay, since if we go back just to migraine or headache itself, the nature of headache is that you have – and this is for a person with not chronic headache, but a person with an episodic headache … Is that they have days nothing is there. No headache, nothing at all. Everything is good. 

[00:28:30] Haidar Al-Khazali: Something occurs in the brain, it starts the headache, right? And even though you don’t treat it with proper medication, it will resolve by itself, for the person with episodic headache or episodic migraine. You don’t need to treat it. It will treat itself. So this is what we call headache has a self-limiting nature. Okay? 

[00:28:49] Leonora Mujkic: Yeah. 

[00:28:49] Haidar Al-Khazali: So this is, the key thing, which is different from, let’s say, if you look at person with sclerosis, a person with dementia, a person with Parkinson. Once they have this problem, it’s not something that comes on and off, on and off.

It’s on, and then it will be on until they maybe die. So that led researchers to think about: since patients report different environmental triggers, since headache has a self-limiting nature by itself, it starts and it disappears by itself, why are we not investigating the molecular triggers?

And that’s basically was the reason for what we are doing here at the headache center. So what we are doing is the thing we call, we use the human provocation model. 

[00:29:30] Haidar Al-Khazali: We think about different molecules, different proteins, for example CGRP, for example PACAP, and then we introduce them to a person with migraine or a person with headache or a control group, and see whether there is different responses.

[00:29:45] Haidar Al-Khazali: And by this approach, we also have always a comparison group within the migraine. So it, it means that the person with migraine will come to two experimental days. One day they will receive, for example, CGRP or PACAP. One day they will receive placebo. So it’s just saline, nothing. But it is double blinded, so me as a scientist, as investigator, and the patient don’t know what the patient receive on both days.

And that was basically the concept that, by this concept we have shown that CGRP and PACAP can induce migraine attacks more than placebo. But we have also investigated other proteins. So this is only two, but we have a list about maybe six or seven or so. Also inducing migraine and that may be higher percentages than CGRP and PACAP.

[00:30:33] Leonora Mujkic: Okay. 

[00:30:33] Haidar Al-Khazali: So we are not interested just … Because for me as a person who wants to really help people with migraine, it’s not nice for me to just call, and recruit a person with migraine and say to them, ”Welcome to my clinic. I will give you more headache.” What should be the purpose for this?

It sounds crazy, right? But the goal will be to understand the mechanisms, what triggers it, and then we can develop treatment either against the receptor or the molecule itself or maybe things within this cell that has a key role in the initiation of the headache. The goal will be in the future is if we have, let’s say, five or six or so different treatments. If we call them let’s say antibodies, an antibody against PACAP, an antibody against another protein, CGRP, a third neuropeptide protein, and so on.

The dream will be that … Because right now a patient with migraine headache, they don’t know what will be the proper treatment for them. They need to test it on themself, right? It’s like a trial. You are in a trial every day. You’re starting, let’s say, with candesartan. You try this for six months or so, and then you see the effect fades out.

Then you switch maybe to another beta blocker or topiramate, an anti-epileptical drug, or antidepressant like amitriptyline. So you can be basically in a trial for many, many years to figure out what is the proper treatment for you. 

[00:32:01] Leonora Mujkic: Yeah. Yeah. If there is one. 

[00:32:03] Haidar Al-Khazali: If there is one. Right. Exactly. 

[00:32:06] Haidar Al-Khazali: Just imagine, the dream will maybe be that we invite the person with migraine and see which of these different proteins could be the biggest driver for the headache. For example, again, for you, let’s say, Malin, for you, it’s CGRP. We figure it out by testing this. We have induced a migraine with you with CGRP, but you were not sensitive to, let’s say, the PACAP experimental day.

But you, Leonora, it was PACAP that was the trigger for your headache. Then I can say to the patient, ”I know what drives your headache. I know it’s exactly this protein. And for this protein, I have this treatment, the proper treatment.” Let’s say antibodies against the PACAP pathway or antibody against the CGRP pathway.

So basically, this is what will be, what will be the dream in the future, that we can individualize the treatment to the individual and not for the entire population should be responsive to one treatment, because we don’t think so. It’s like we say, there are more than one road to Rome, and the same goes with migraine.

There is more than one road to migraine. Yeah. For some people, it’s one protein. For some, it will be maybe a combination of both CGRP and PACAP. Yeah. For one, it will be four different. And we don’t know now. This is why we are doing the type of research we are doing. 

[00:33:23] Malin Östblom: Amazing. We accept the invitation. We are already on a plane to Copenhagen.

End of interview with Haidar Al-Khazali

Leonora: Well, that was a lot to take in, but so much fun to learn about. Where do we even start?

Malin: I don’t know. Maybe by accepting that we probably won’t understand all of it, but we can try to pick out a few things and dig into them a bit.

Leonora: I think that’s right. If we try to sum up the interview really briefly, I’d say the core of it is this: just like CGRP inhibitors block the substance CGRP, researchers are now developing PACAP inhibitors, which block the substance PACAP. So they’re two different substances, CGRP and PACAP, but the drugs are meant to work in the same way. Would you agree with that description?

Malin: Yes, I do. I thought the analogy with the doors and the keyholes was a really good way to picture how they work, and at what level. Other than that, what are your thoughts?

Leonora: I’ve been hearing about PACAP for several years now, so it’s great to finally learn a bit more about how the research is going. I feel so grateful to the people who actually agreed to be given an infusion that would most likely trigger a migraine attack. They’re the ones who made this research possible. What about you, what are your thoughts?

Malin: I think this is the future. It might be too late for me, but for people who get a migraine diagnosis today, or for my son, who’s 13, treatment options might look completely different thanks to the discovery of PACAP. I say ”might”, because we don’t know yet how this will develop. But of course, my son’s treatment options will be different anyway, since we now have CGRP inhibitors and gepants. And now we’re hoping for PACAP too. The fact that researchers keep pushing forward, that’s what’s so amazing.

Leonora: It really is. And listening to Haidar, it also becomes so clear how long it takes, and how hard it is, to bring a new drug to market. But what Haidar tells us really gives hope.

Malin: Absolutely! I can’t help thinking of Lars Edvinsson and his sheer grit. It feels like Haidar has quite a lot of grit too.

Leonora: Yes, and lots of colleagues who are all working towards the same goal: a better life for those of us with migraine.In the next episode, you’ll hear the second part of our interview with Haidar Al-Khazali. He talks about when we can expect PACAP inhibitors as new drugs, if everything goes well. What’s extra exciting is that Haidar also talks about how PACAP affects cluster headache and post-traumatic headache, because there seem to be some similarities with migraine there.

Leonora: That’s right. Bye for now!

Malin: Talk to you soon!